Demographic and Clinical Data | PRa (n = 367) | Controls(n = 2029) | t/Z/χ2 | p value |
---|---|---|---|---|
Preoperative Period | ||||
 Age at Diagnosis (Years) | 54.61 (13.29), 6.00–78.00 | 43.25 (13.93), 3.00–82.00 | t = 14.95 | < 0.0001**** |
 Sex male No. (%) | 245 (67) | 1152 (57) | χ2 = 12.74 | 3.59 × 10− 4*** |
 Illness Duration (Months) | 3.97 (15.74), 0.10–240.00 | 5.73 (14.40), 0.05–240.00 | t = -1.96 | 0.05 |
 Headache No. (%) | 184 (50) | 754 (37) | χ2 = 21.96 | < 0.0001**** |
 Dizziness No. (%) | 44 (12) | 288 (14) | χ2 = 1.27 | 0.26 |
 Nausea No. (%) | 16 (4) | 75 (4) | χ2 = 0.37 | 0.54 |
 Vomiting No. (%) | 32 (9) | 142 (7) | χ2 = 1.37 | 0.24 |
 Epilepsy No. (%) | 8 (2) | 161 (8) | χ2 = 15.70 | < 0.0001**** |
 Intracranial Space-Occupying Lesion or Intracranial Tumora No. (%) | 6 (2) | 125 (6) | χ2 = 12.32 | 4.49 × 10− 4*** |
 Impaired Consciousness No. (%) | 41 (11) | 416 (21) | χ2 = 17.53 | < 0.0001**** |
 Muscle Twitching No. (%) | 39 (11) | 439 (22) | χ2 = 23.59 | < 0.0001**** |
 Muscle Weakness No. (%) | 84 (23) | 232 (11) | χ2 = 35.61 | < 0.0001**** |
 Limb Numbness No. (%) | 23 (6) | 125 (6) | χ2 = 0.01 | 0.94 |
 Speech Disorder No. (%) | 46 (13) | 145 (7) | χ2 = 12.30 | 4.54 × 10− 4*** |
 Memory Deterioration No. (%) | 32 (9) | 78 (4) | χ2 = 16.86 | < 0.0001**** |
 Slow Reaction No. (%) | 22 (6) | 31 (2) | χ2 = 28.67 | < 0.0001**** |
 Visual Impairment No. (%) | 20 (5) | 90 (4) | χ2 = 0.73 | 0.39 |
 Lethargy No. (%) | 4 (1) | 9 (0) | Z = -1.54 | 0.12 |
 Family History of Glioma No. (%) | 1 (0) | 0 (0) | Z = -1.42 | 0.15 |
Respiratory Diseases No. (%) | 0 (0) | 0 (0) | -- | -- |
 Digestive Diseases No. (%) | 1 (0) | 0 (0) | Z = -1.45 | 0.15 |
 Urinary System Diseases No. (%) | 0 (0) | 2 (0) | Z = 0.00 | 1.00 |
 Hematological Disorders No. (%) | 0 (0) | 0 (0) | -- | -- |
 Endocrine Diseases No. (%) | 0 (0) | 1 (0) | Z = 0.00 | 1.00 |
 Cardiovascular Diseases No. (%) | 1 (0) | 3 (0) | Z = -0.71 | 0.47 |
 Previous Surgical History No. (%) | 13 (4) | 21 (1) | χ2 = 13.75 | 2.09 × 10− 4*** |
 History of Head Trauma No. (%) | 0 (0) | 6 (0) | Z = -0.53 | 0.60 |
Tumor Location | ||||
 Frontal lobe No. (%) | 155 (42) | 1112 (55) | χ2 = 19.71 | < 0.0001**** |
 Parietal lobe No. (%) | 55 (15) | 274 (14) | χ2 = 0.58 | 0.45 |
 Occipital lobe No. (%) | 38 (10) | 122 (6) | χ2 = 9.40 | 2.17 × 10− 3** |
 Temporal lobe No. (%) | 152 (41) | 580 (29) | χ2 = 24.12 | < 0.0001**** |
 Insular lobe No. (%) | 23 (6) | 161 (8) | χ2 = 1.22 | 0.27 |
 Corpus Callosum No. (%) | 30 (8) | 64 (3) | χ2 = 20.78 | < 0.0001**** |
 Thalamus No. (%) | 15 (4) | 31 (2) | χ2 = 10.81 | 1.01 × 10− 3** |
 Basal ganglia No. (%) | 6 (2) | 37 (2) | χ2 = 0.06 | 0.80 |
 Brainstem No. (%) | 0 (0) | 10 (0) | Z = -0.88 | 0.38 |
 Cerebellum No. (%) | 6 (2) | 47 (2) | χ2 = 0.67 | 0.41 |
 Ventricle No. (%) | 12 (3) | 61 (3) | χ2 = 0.07 | 0.79 |
 Karnofsky Scoreab (%) | 80.98 (14.88), 30.00-100.00 | 84.91 (12.03), 40.00-100.00 | t = 4.77 | < 0.0001**** |
Postoperative Period | ||||
 WHO Grade 1/2/3/4 | 1/24/42/300 | 73/896/403/657 | χ2 = 327.14 | < 0.0001**** |
 WHO Grade 1 No. (%) | 1 (0) | 73 (4) | χ2 = 11.48 | 7.03 × 10− 4*** |
 WHO Grade 2 No. (%) | 24 (7) | 896 (55) | χ2 = 185.95 | < 0.0001**** |
 WHO Grade 3 No. (%) | 42 (11) | 403 (20) | χ2 = 14.56 | 1.36 × 10− 4*** |
 WHO Grade 4 No. (%) | 300 (82) | 657 (32) | χ2 = 315.70 | < 0.0001**** |
 GFAP + a No. (%) | 345 (96) | 1948 (97) | χ2  = 1.47 | 0.23 |
 OLIG2 + a No. (%) | 244 (68) | 1593 (80) | χ2 = 25.16 | < 0.0001**** |
 P53 + a No. (%) | 197 (55) | 923 (47) | χ2 = 9.20 | 2.43 × 10− 3** |
 IDH-1/IDH-2 + a No. (%) | 34 (12) | 798 (49) | χ2 = 129.91 | < 0.0001**** |
 Ki-67a ≥ 20% No. (%) | 99 (28) | 294 (15) | χ2 = 36.78 | < 0.0001**** |
 TERT + a No. (%) | 79 (54) | 483 (54) | χ2 = 0.01 | 0.91 |
 1p/19q Codeletiona No. (%) | 2 (2) | 92 (12) | χ2 = 12.16 | 4.87 × 10− 4*** |
 MGMT + a No. (%) | 95 (33) | 638 (42) | χ2 = 8.27 | 4.03 × 10− 3** |
 EGFR + a No. (%) | 28 (93) | 84 (73) | χ2 = 5.57 | 0.02* |
 Hospitalization Days | 19.58 (10.16), 3.00–99.00 | 18.05 (8.07), 2.00–131.00 | t = -2.70 | 0.01* |
 Chemotherapy/Radiotherapy No. (%) | 237 (65) | 1674 (83) | χ2 = 61.86 | < 0.0001**** |
 Karnofsky Scoreab (%) | 82.35 (18.93), 30.00-100.00 | 90.63 (12.87), 20.00-100.00 | t = 7.52 | < 0.0001**** |
 ECOG Gradea | 1.19 (0.91), 0.00–4.00 | 0.76 (0.70), 0.00–4.00 | t = -7.92 | < 0.0001**** |